Abstract. The AKT pathway serves important roles in tumor cell growth. Its overexpression is associated with poor prognosis in a number of types of cancer; however, the role of AKT in the role of the pathogenesis of hepatocellular carcinoma (HCC) remains unclear. The present study was undertaken to explore the clinical relevance of phosphorylated AKT (p-AKT) in HCC. The level of p-AKT in tumor (TU) and paired adjacent normal liver (AN) tissue from 202 HCC patients was evaluated with immunohistochemistry. The results demonstrated that p-AKT was more highly expressed in TU than in AN tissue. Kaplan-Meier curves and Cox regression revealed that patients with a high expression of p-AKT (AN) exhibited reduced overall and relapse-free survival times; this was not observed at a statistically significant level in p-AKT (TU). Additionally, the high expression of p-AKT (AN) was positively correlated with hepatitis C virus (HCV) infection in HCC patients. These results support the hypothesis that AKT activation is a mechanism of HCV-induced hepatocarcinogenesis, suggesting that AKT can be a therapeutic target for the treatment of recurrent HCC subsequent to surgical resection.
Introduction
Hepatocellular carcinoma (HCC) is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer-associated mortality worldwide (1) . It is generally more common in non-Caucasian populations (1) . Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), alcoholic liver disease and non-alcoholic fatty liver disease have been associated with the tumorigenesis of HCC (2) . HCC is an inflammation-associated cancer that generally develops in the background of chronic hepatitis, regardless of the triggering etiology (3) .
Inflammation-induced HCC is dependent on AKT activation (4, 5) . AKT, also called protein kinase B, is a serine/threonine kinase. Phosphorylated AKT (p-AKT), the active form of AKT, influences a range of cellular functions, including cell growth, proliferation, differentiation, motility, survival and intracellular trafficking (6) . Previous studies have indicated that the increased immunohistochemical expression of p-AKT is correlated with a poorer prognosis in various types of cancer, including endometrial carcinoma (7), renal cell carcinoma (8) , colorectal cancer (9) , breast cancer (10), melanoma (11) and nasopharyngeal carcinoma (12) . In HCC, the upregulation of AKT1, 2 or 3 has been demonstrated to be significantly associated with tumor progression and a poor survival rate (13) .
p-AKT may be a target for therapeutic regimens aiming to reverse acquired resistance to sorafenib during the treatment of patients with HCC (14) (15) (16) . Although p-AKT expression in tumor tissue (TU) was previously explored (13) , the role for p-AKT in the adjacent non-neoplastic liver tissue (AN) remains unidentified. The aim of the present study was to apply immunohistochemical staining for p-AKT to clinical samples of TU and AN tissues, to investigate the clinical significance in patients with HCC. Survival time was defined as period from the date of primary surgery to the date of patient mortality or disease recurrence. Due to the retrospective nature of the study, clinical data was obtained through chart review, and some information was incomplete; among the 202 HCC patients, HCV status was unknown for 8 and HBV serum antigen status was unknown for 7. The median follow-up time subsequent to surgery was 907 days; the median OS time of all patients was 937 days. A total of 44 patients succumbed to HCC during the study. On the basis of follow-up data, 8 patients relapsed, with local recurrence.
Patients and methods

Patients
Immunohistochemistry (IHC) and scoring. IHC was used to detect p-AKT protein expression. The IHC procedures were conducted as previously described (18), using an anti-p-AKT antibody (sc-16646-R) purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Negative controls were obtained by performing all IHC steps without the primary antibody. The IHC staining intensities were evaluated by a board-certified pathologist. Immunostaining scores were defined as the cell staining intensity (nil, 0; weak, 1; moderate, 2; strong, 3) multiplied by the percentage of labeled cells (0-100%), producing scores between 0-300. A score greater than the mean was defined as 'high' immunostaining, whereas a score less than or equal to the mean was categorised as 'low', respectively for AN and TU tissues.
Statistical analysis. All statistics were performed with SPSS software (version 18.0; SPSS, Inc., Chicago, IL, USA). Survival curves were plotted using the Kaplan-Meier method and variables associated with survival were analyzed with Cox's proportional hazards regression model. Statistical differences in survival data were analyzed using the log-rank test. P<0.05 was considered to indicate a statistically significant difference.
Results
p-AKT expression is higher in TU than in AN.
A total of 202 HCC patients were enrolled in the present study. p-AKT expression was detected using IHC in 202 sets of paired TU and AN tissues (Fig. 1 ). p-AKT expression level in TU tissue (p-AKT TU) was significantly higher than in the paired AN tissue (p-AKT AN; P<0.001; Fig. 2 ). The mean IHC score was 179 for TU and 81 for AN; these scores were used as cut-off values for high and low expression in the respective groups.
p-AKT (AN) is positively associated with hepatitis c virus infection.
Statistical analysis was performed to verify whether p-AKT (AN) and p-AKT (TU) were linked with clinicopathological parameters including age, sex, differentiation grade, tumor stage, HBV surface antigen and HCV status. Only HCV status was significantly associated with p-AKT (AN); Patients with HCC that exhibited HCV infection had a higher expression of p-AKT (AN) than those without HCV infection (P=0.026; Table I ). The results of the present study suggest that the effect of HCV infection on p-AKT (AN) expression was more evident than on p-AKT (TU).
p-AKT (AN) is associated with OS and RFS time in HCC
patients. The association of p-AKT (AN) and clinicopathological parameters, including age, sex, differentiation, stage, HBV surface antigen, HCV, p-AKT (TU) and p-AKT (AN), with patient survival time was investigated by univariate analysis The full results are included in Table II . OS time was significantly associated with stage (P<0.001) and p-AKT (AN) (P= 0.011); RFS was significantly associated with stage (P<0.001) and p-AKT (AN) (P=0.050). It was then examined whether p-AKT (AN) expression was associated with clinical outcomes in HCC patients. Kaplan-Meier analysis demonstrated that patients with high p-AKT (AN) had shorter OS and RFS periods when compared with patients with low p-AKT (AN) (P=0.011 and P=0.050, respectively; Table II; Fig. 3 ), whereas p-AKT (TU) was not significantly associated with survival time. Cox regression analysis indicated a prognostic significance for p-AKT (AN) in OS and RFS in the study population (P=0.011 and P=0.046, respectively; Table III ). The hazard ratios for high p-AKT (AN) were 2.192 for OS and 1.751 for RFS, respectively, relative to low p-AKT (AN) (Table III) . Additionally, the hazard ratios for stage III/IV were 3.064 for OS and 3.536 for RFS, respectively, relative to stage I/II (both P<0.001; Table III ). The results suggest that p-AKT (AN) expression may promote tumor malignancy, resulting in poor outcomes for patients with HCC.
Discussion
Based on the data of the present study, post-resection patients with HCV-associated HCC exhibit higher p-AKT (AN) expression than those without HCV infection. p-AKT (AN) may be a predictor for prognosis and recurrence in HCC. These results support a previous study in which patients positive for HCV undergoing the resection of HCC experienced reduced OS and RFS times relative to patients negative for HCV (19) . HCV is a single-stranded, positive-sense RNA virus of the Flaviviridae family; HCV-induced HCC is expected to increase in the next Table I . Association of clinical parameters with p-AKT expression of AN and TU tissue in hepatocellular carcinoma patients. two decades (20, 21) . Examinations of the association between HCV and the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway has revealed that the HCV-associated NS5A protein binds to PI3K, consequently activating AKT and potentially contributing to the development of HCC (22,23).
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One study identified that HCV rapidly and transiently activated AKT in the early stage of infection via the interaction between the HCV E2 envelope protein and its co-receptors CD81 and claudin-1, with the effect of enhancing viral entry into the cell (24). Table II . Univariate analysis of influences of clinical characteristics, and p-AKT (AN) or (TU), on OS and RFS in hepatocellular carcinoma patients. Another study reported that cancer stem cells or tumor-initiating cells that retain a stem cell-like phenotype, along with the HCV-induced reprogramming of liver cells, may contribute to hepatocarcinogenesis in an animal model (25) . AKT serves an additional role in the maintenance of stem-like characteristics, the mesenchymal phenotype and the self-renewal of these cells via the AKT/Forkhead box O/Bcl2-like 11 pathway (26) . Therefore, the observation that higher p-AKT (AN) may be an independent prognostic factor for HCC may be due to HCV infection.
In summary, the present study revealed that patients with HCC with high levels of p-AKT (AN) expression exhibited a relatively poor survival rate, and p-AKT (TU) was significantly higher than p-AKT (AN). Curing HCV and inhibiting p-AKT may be necessary to improve the outcome for patients with HCC.
